Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.

Bosnian journal of basic medical sciences / Udruženje basičnih mediciniskih znanosti = Association of Basic Medical Sciences

Volumn 7, Issue 2, 2007, Pages 111-116

  Ljuca, Dzenita ^a   Fatusić, Zlatan ^a   Iljazović, Ermina ^a   Ahmetović, Begzudin ^a  

^a UNIVERSITY CLINICAL CENTER TUZLA   (Bosnia and Herzegovina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CELL SURFACE RECEPTOR; CISPLATIN; PACLITAXEL; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS; UNCLASSIFIED DRUG; UROKINASE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; COLLOID CARCINOMA; DOSE RESPONSE; FEMALE; HUMAN; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, CELL SURFACE; TREATMENT OUTCOME; URINARY PLASMINOGEN ACTIVATOR;

EID: 34447506468     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)